PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x. AUTHORS: R. Wuerstlein, R. Kates, O. Gluz, E.M. Grischke, C. Schem, M. Thill, S. Hasmueller, A. Köhler, B. Otremba, F. Griesinger, C. Schindlbeck, A. Trojan, F. Otto, M. Knauer, R. Pusch, N. Harbeck, WSG-PRIMe investigators in Germany, Austria, Switzerland SUMMARY: MammaPrint Read More

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

PUBLICATION: npj Breast Cancer; volume 5, Article number: 15 (2019). AUTHORS: Floris H. Groenendijk, Tina Treece, Erin Yoder, Paul Baron, Peter Beitsch, William Audeh, Winand N. M. Dinjens, Rene Bernards & Pat Whitworth ABSTRACT: Immunohistochemically ER-positive HER2-negative (ER+HER2−) breast cancers are classified clinically as Luminal-type. We showed previously that molecular Read More

2018 SABCS FLEX Trials in Progress Poster

AUTHORS: Adam M. Brufsky, Jennifer A. Crozier, Ian Grady, Thomas Lomis, Pat Whitworth, Esther Rehmus, Gordon Srkalovic, Laura Lee, Peter Blumencranz, Paul Baron, Blanche Mavromatis, Sarah Untch, Lisa Blumencranz, Tina Treece, Erin Yoder, William Audeh. DESCRIPTION: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Read More

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

AACR, Poster 2612 AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Denise Wolf, Christina Yau, William Audeh, Annuska Glas, Lamorna Brown-Swigart, Gillian Hirst, Angela DeMichele, ISPY2 TRIAL Investigators, Laura Esserman and Laura van ‘t Veer DESCRIPTION: BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY2 breast cancer patients BluePrint® Read More

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

PUBLICATION: JAMA Oncol. 2018; 4(1):e173470. doi:10.1001/jamaoncol.2017.3470. AUTHORS: Michaela Tsai, MD; Shelly Lo, MD; William Audeh, MD; Rubina Qamar, MD; Raye Budway, MD; Ellis Levine, MD; Pat Whitworth, MD; Blanche Mavromatis, MD; Robin Zon, MD; Dwight Oldham, MD; Sarah Untch, MS; Tina Treece, PhD; Lisa Blumencranz, PhD; Hatem Soliman, MD ABSTRACT: Read More